Acquired had a great episode earlier this year that really connects with this. They talked about how Novo Nordisk stuck with GLP-1 research for decades, even when it didn’t seem like a sure thing.
A big part of that was Mads Krogsgaard Thomsen, who pushed for GLP-1 research at Novo even when he faced a lot of skepticism and wasn't always treated well for it. Compare that with MetaBio—mentioned in the study—where Pfizer pulled the plug early and missed the boat entirely. Novo’s persistence, especially Thomsen's, led to Ozempic and Wegovy
A big part of that was Mads Krogsgaard Thomsen, who pushed for GLP-1 research at Novo even when he faced a lot of skepticism and wasn't always treated well for it. Compare that with MetaBio—mentioned in the study—where Pfizer pulled the plug early and missed the boat entirely. Novo’s persistence, especially Thomsen's, led to Ozempic and Wegovy